Qiming Medical - B (02500. HK) medium-term income of 256 million yuan increased by 21.7% year on year

(Data pictures are for reference only)

On August 31, Gelonghui Qiming Medical - B (02500. HK) announced that the company's revenue in the six months ended June 30, 2023 was RMB 256 million, up 21.7% year on year. The above increase is mainly due to the continuous promotion of commercialization of VenusA series products and VenusP Valve's increasing penetration into overseas markets during the reporting period. The loss during the period was 366 million yuan, compared with 240 million yuan in the same period last year.

As of June 30, 2023 and 2022, the company's R&D expenses were 294.7 million yuan and 220.3 million yuan respectively.

The company attaches great importance to intellectual property protection. With its strong R&D capability, as of August 31, 2023, the company has a total of 896 patents and patent applications, including 397 authorized invention patents. The number of patent applications and authorizations of companies in China is 373, of which 235 are authorized; The number of patent applications and authorizations of overseas companies is 492, of which 314 are authorized; There are 31 PCT applications. The main countries and regions of patent layout are: China, the United States, Europe, Japan, Canada, Russia, India, Brazil, etc.

label: